表紙:BENRALIZUMAB:新しい慢性特発性蕁麻疹治療薬の分析・予測 (~2030年)
市場調査レポート
商品コード
974749

BENRALIZUMAB:新しい慢性特発性蕁麻疹治療薬の分析・予測 (~2030年)

BENRALIZUMAB- Emerging Insight and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 60 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.41円
BENRALIZUMAB:新しい慢性特発性蕁麻疹治療薬の分析・予測 (~2030年)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 60 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

慢性特発性蕁麻疹治療薬の市場は世界中での広範な研究と医療費の増加により、今後数年で規模を拡大する見通しであり、医薬品メーカーはより多くの市場に参入できるようになると予測されています。

当レポートでは、新しい慢性特発性蕁麻疹治療薬であるBENRALIZUMABの主要7カ国 (米国・ドイツ・フランス・イタリア・スペイン・英国・日本) における展望を調査し、製品概要、作用機序、臨床開発・臨床試験の動向、関連法規制、特許動向、売上予測、競合状況、SWOT分析、アナリストの見解などをまとめています。

第1章 薬剤の概要

  • 製品概要
  • 作用機序
  • 投薬・管理
  • R&D活動
    • 臨床開発
    • 安全性・有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国市場の分析
  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第3章 SWOT分析

第4章 アナリストの見解

第5章 競合事業者

第6章 他の新しい治療薬

第7章 付録

第8章 購入オプション

図表

List of Tables

  • Table 1 BENRALIZUMAB, Description
  • Table 2 BENRALIZUMAB, Clinical Trial Description
  • Table 3 BENRALIZUMAB, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of BENRALIZUMAB
  • Figure 2 Patent Details, BENRALIZUMAB
  • Figure 3 BENRALIZUMAB, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 BENRALIZUMAB, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 BENRALIZUMAB, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 BENRALIZUMAB, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0130

"BENRALIZUMAB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the BENRALIZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

Fasenra is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death). Fasenra is AstraZeneca's first respiratory biologic, now approved as an add-on maintenance treatment for severe eosinophilic asthma in the US, EU, Japan and other countries, with further regulatory reviews ongoing. In the US, Fasenra is approved for self-administration in the Fasenra Pen. In the EU, Fasenra is approved for self-administration in either the single-use, pre-filled syringe or the Fasenra Pen. Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa Kirin Co., Ltd., Japan.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around BENRALIZUMAB.
  • The report contains forecasted sales for BENRALIZUMAB till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Chronic Spontaneous Urticaria.
  • The report also features the SWOT analysis with analyst insights and key findings of BENRALIZUMAB.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BENRALIZUMAB Analytical Perspective by DelveInsight

  • In-depth BENRALIZUMAB Market Assessment

This report provides a detailed market assessment of BENRALIZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • BENRALIZUMAB Clinical Assessment

The report provides the clinical trials information of BENRALIZUMAB covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence BENRALIZUMAB dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Chronic Spontaneous Urticaria are giving market competition to BENRALIZUMAB and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of BENRALIZUMAB.
  • Our in-depth analysis of the forecasted sales data of BENRALIZUMAB from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BENRALIZUMAB.

Key Questions:

  • Which company is developing BENRALIZUMAB along with the phase of the clinical study?
  • What is the technology utilized in the development of BENRALIZUMAB?
  • What is the product type, route of administration and mechanism of action of BENRALIZUMAB?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BENRALIZUMAB development?
  • What are the key designations that have been granted to BENRALIZUMAB?
  • What is the forecasted market scenario of BENRALIZUMAB?
  • What is the history of BENRALIZUMAB and what is its future?
  • What is the forecasted sales of BENRALIZUMAB in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to BENRALIZUMAB?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options